FDA has approved Darzalex (daratumumab) in combination with Velcade (bortezomib), a proteasome inhibitor; melphalan, an alkylating agent; and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
The European Medicines Agency has approved LYNPARZA (olaparib) tablets (300 mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy, regardless of BRCA status.
FDA has accepted the company's supplemental Biologics License Application and granted Priority Review for Tecentriq (atezolizumab), in combination with Avastin (bevacizumab), paclitaxel and carboplatin, for the initial treatment of people with metastatic non-squamous non-small cell lung cancer.
Eli Lilly and Co. and ARMO BioSciences Inc. announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction.
FDA approved Kymriah (tisagenlecleucel) suspension for intravenous infusion for its second indication – the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
The FDA granted regular approval to Tafinlar (dabrafenib) and Mekinist (trametinib) in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node, following complete resection.
Regeneron Pharmaceuticals Inc. and Sanofi today announced the FDA has accepted for priority review the Biologics License Application for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma or patients with locally advanced CSCC who are not candidates for surgery.
Genocea Biosciences Inc., the biopharmaceutical company developing neoantigen cancer vaccines, announced the filing of an Investigational New Drug Application with the FDA to begin a Phase I/IIa clinical program testing the safety, immunogenicity, and clinical efficacy of GEN-009, the company's lead personalized neoantigen cancer vaccine candidate.
The European Commission approved Mylotarg (gemtuzumab ozogamicin) in combination with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo, CD33-positive acute myeloid leukemia, except acute promyelocytic leukemia.
Nektar Therapeutics and Takeda Pharmaceutical Co. Ltd. join a clinical collaboration to evaluate Nektar's investigational medicine, NKTR-214, with Takeda's investigational medicine, TAK-659, as a potential combination treatment regimen in multiple cancer settings.
